Detail of "104138-64-9"

Reference

Self-buffering protein formulations

All Rights Reserved. Self-buffering protein formulations. Gokarn, Yatin R. 104138-64-9 and 181054-95-5 are also occured in this study.; Kras, Eva; Remmele, Richard Louis, Jr.; Brems, David N.; Hershenson, Susan Irene (Amgen Inc., USA). PCT Int. Appl. WO 2006138181 A2 28 Dec 2006, 104pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-US22599 8 Jun 2006. PRIORITY: US 2005-690582P 14 Jun 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addn. to other advantages, the formulations avoid the disadvantages assocd. with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, esp., in particular, for the treatment of diseases in humans. .

Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey

All Rights Reserved. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Hajioff, D.; Hegemannn, S.; Conti, G.; Beck, M.; Sunder-Plassmann, G.; Widmer, U.; Mehta, A.There are some reagents like 104138-64-9 is used in this study.; Keilmann, A. (Department of Otolaryngology, Southmead Hospital, Bristol, UK). European Journal of Clinical Investigation, 36(9), 663-667 (English) 2006 Blackwell Publishing Ltd. CODEN: EJCIB8. ISSN: 0014-2972. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 14 Background: Fabry disease is an X-linked lysosomal storage disorder characterized by multi-organ dysfunction, including hearing loss - mainly sensorineural. The recent introduction of enzyme replacement therapy (ERT) has resulted in improvements in renal and cardiac function, pain and quality of life. One study has also suggested small improvements in high-frequency hearing. In this paper, we study the effect of ERT on hearing in patients in the Europe-wide database - the Fabry Outcome Survey (FOS). Materials and methods: Twenty-six patients in FOS had pure-tone audiometry performed up to 6 mo before starting ERT with agalsidase alpha and after a median of 12 mo of treatment. We assessed changes in hearing thresholds, expressed as deviations from the 50th centile of the normal population (International Organization for Standardization ISO 7029) to correct for age-related non-specific hearing deterioration. Results: Hearing did not change significantly in ears with normal hearing (less than 10 dB deviation from the 50th centile of ISO 7029) or those with severe hearing loss (more than 40 dB deviation from the 50th centile of ISO 7029) at baseline. In ears with a mild or moderate hearing loss at baseline, hearing thresholds, expressed as deviations from the normal 50th centile, improved significantly by 4-7 dB at most frequencies (P < 0.05). Conclusions: Agalsidase alpha stabilizes, and possibly improves, hearing in Fabry patients who have not already progressed to severe hearing loss. Further follow-up of these patients will det. the longer-term effects of ERT. .